Pfizer Inc, a second largest pharmaceutical company in the world after
Novartis, has suffered heavy setback during the second quarter ended
June 2014 on account of one time income received from sell of animal
health business, Zoetis Inc., for a consideration of $10.4 billion in
the last period. The net profit declined by 79.3 per cent to $2,912
million from $14,095 million in the corresponding quarter of last year.
Its revenues also declined by 1.5 per cent to $12,773 million from
$12,973 million due to multi-source generic competition for Celebrex in
the US and destocking by wholesaler and retailer.The company began managing its commercial operations through a new global commercial structure consisting of three operating segments viz., Global Innovative Pharmaceuticals Segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP).
